TL;DR
Get comfort and recovery gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A guest post by LabCentral’s Kamran Tavangar compares quantum computing’s early role in biotechnology with the Fosbury Flop’s development in high jumping. He describes one AI BioHub company testing quantum computing in a breast cancer model, while emphasizing that the work remains early and requires more data, expertise and infrastructure.
A guest post published by The Quantum Insider on October 30 argues that quantum computing is still at an early stage in biotechnology, despite emerging efforts to combine it with artificial intelligence and biological research. Kamran Tavangar, LabCentral’s head of science strategy and partnerships, points to one company in LabCentral’s AI BioHub cohort using quantum computing in a model of triple-negative breast cancer, but says broader impact will depend on more than advances in quantum hardware.
Tavangar says the company is using quantum computing in a virtual disease model for triple-negative breast cancer, with the aim of predicting drug therapy options for individual patients. He describes the results as “encouraging,” while noting that the team is still refining its models with retrospective and prospective data and working toward proof of concept. The article does not report clinical findings or establish that the model can guide patient treatment.
The example is unusual within the program: Tavangar says one of the 30 early-stage companies in the AI BioHub cohort was actively using a quantum computer. In his account, access remains difficult and expensive, and expertise that connects quantum computing with biology is not widespread. He expects a hybrid CPU-GPU-QPU approach—combining conventional processors, graphics processors and quantum processors—to remain the preferred approach for the foreseeable future.
The article frames quantum as a possible addition to an existing AI-driven cycle. AI models use biological data to generate predictions and questions; laboratory experiments can then supply additional data to refine those models. Tavangar argues that turning scientific capability into a practical breakthrough also requires funding, manufacturing, regulation and partnerships, alongside the research itself.
What Quantum Could Add to Biotech
The article’s significance lies less in a demonstrated medical result than in its account of the work needed to make quantum computing useful in biotechnology. The cancer-model example is an early application, not evidence that quantum systems already outperform conventional computing or improve patient outcomes. Tavangar says simulated quantum algorithms can perform at least as well as, or better than, current quantum computers, while improvements in GPUs and classical software continue to advance existing methods.
For biotech researchers and companies, that distinction matters: near-term work may involve testing quantum components as part of hybrid systems rather than replacing classical computers. Tavangar’s argument is that the potential value depends on a broader innovation system, including biological data, laboratory validation, technical expertise and reliable access. Without those pieces, improvements in processors alone may not translate into new treatments or better disease models.
The article also presents a workforce and infrastructure challenge. If only one company in the cohort was using a quantum computer, then the field’s development will require people who understand both biology and quantum computing, as well as collaborators able to connect those disciplines. The piece treats those capabilities as part of the path to future applications, not as proof that a breakthrough is imminent.
Products Worth Considering
Sonos Era 100 SL Compact, Microphone-Free Speaker – Black
Sony BRAVIA 5 85-Inch Mini LED 4K HDR Smart TV (K-85XR50)
TCL T7 Series 85-Inch 4K 144Hz QLED Smart Google TV
As an affiliate, we earn on qualifying purchases.
From High-Jump Technique to Biotech
Tavangar uses the Fosbury Flop as an analogy for technology development. At the 1968 Mexico City Olympics, Dick Fosbury cleared 2.24 meters using a backward high-jump technique and won gold. The guest post says his approach was supported by cushioned landing pads, which replaced sand or wood-chip pits, and that the technique developed through years of practice before becoming widely adopted.
The comparison is about the combination of an unconventional method with enabling equipment and continued refinement. Tavangar says quantum computing in biotech is at an earlier stage: promising enough to test, but not yet established as a standard tool. He also notes that the high-jump record later reached 2.45 meters through changes in both equipment and technique. In his analogy, quantum hardware is only one part of a wider system of algorithms, software, expertise and partnerships.
The guest post places this argument within the growth of biotech AI. It cites AlphaFold as an example of a system trained using decades of experimentally determined protein structures in the Protein Data Bank. Tavangar also describes LabCentral’s AI BioHub, developed with support from the Commonwealth of Massachusetts and in partnership with C10 Labs, as a program in which 30 early-stage companies explored AI-focused biotechnology.
““Early results are encouraging,””
— Kamran Tavangar, LabCentral’s head of science strategy and partnerships
Evidence Still at Proof of Concept
The guest post does not provide performance measurements for the breast cancer model, explain how its predictions compare with existing methods, or report that its results have been validated in clinical care. Tavangar says the company is incorporating retrospective and prospective data and moving toward proof of concept, but does not specify a timeline or define what evidence would count as success.
It is also unclear from the article which quantum hardware or algorithms the company uses, how much of the model’s work runs on a quantum processor, or whether the approach has produced an advantage over classical computing. The post makes a general case for hybrid systems and describes potential future capabilities, but it does not establish when quantum computers will reach fault tolerance or how quickly their use in biotech may expand.
Model Testing and System Development
The company described by Tavangar is continuing to refine its model using retrospective and prospective data and working toward proof of concept. The guest post does not give a date for that milestone or specify when results will be published. Readers should look for future evidence about model performance, comparisons with classical approaches and validation of its predictions.
More broadly, Tavangar calls for continued development of expertise, infrastructure and partnerships that connect quantum computing with biotechnology. He expects improvements in quantum processors to progress alongside advances in classical computing, software and algorithms. Whether that combination leads to practical disease models or treatment applications remains to be demonstrated.
Key Questions
What is the biotech development described in the article?
LabCentral’s Kamran Tavangar says one company in the AI BioHub cohort is using quantum computing within a virtual disease model for triple-negative breast cancer, with the goal of predicting drug therapy options for individual patients.
Has the cancer model been shown to guide patient treatment?
No such result is reported. Tavangar says the company is refining the model with retrospective and prospective data and working toward proof of concept. The post does not report clinical validation or patient outcomes.
How common was quantum computing among the AI BioHub companies?
Tavangar says one of the cohort’s 30 early-stage companies was actively using a quantum computer. The article describes access as difficult and expensive and says cross-disciplinary expertise remains limited.
Does the article say quantum computers are outperforming classical systems?
No. Tavangar says simulated quantum algorithms can match or outperform current quantum computers, while advances in GPU hardware, software and algorithms continue to strengthen classical computing. He expects hybrid systems to remain the preferred approach for the foreseeable future.
Source: thequantuminsider.com
